Key Highlights

  • LifeMD climbed 36.56% to USD 2.26 in Friday trading on November 13, 2026, per market data, suggesting a prior close near USD 1.66 (calculated) after results came out on November 12.
  • Third quarter Revenue dipped to USD 44.6 million from USD 47.7 million, while the net loss totaled USD 5.2 million, equal to USD 0.11 per share, against USD 0.12 a share one year earlier.
  • Adjusted EBITDA was a loss of roughly USD 0.41 million, versus USD 2.79 million of profit a year before, though it improved by about USD 3.1 million from the USD 3.5 million second quarter loss.
  • Full-year 2026 revenue forecasts were cut: the range is now USD 188 million to USD 191 million, down from USD 205.5 million to USD 212.5 million. Adjusted EBITDA is now projected to fall between a USD 12.6 million loss and a USD 10.6 million loss.

A Narrower Loss Arrives Alongside Lower Sales

LifeMD (NASDAQ:LFMD) rose 36.56% to USD 2.26 on Friday, November 13, 2026, after posting third quarter numbers on November 12. Revenue of USD 44.6 million was about 6.5% lower than USD 47.7 million (calculated); pre-report published estimates pegged it near USD 48.8 million, implying a shortfall. The net loss of USD 5.2 million, or USD 0.11 a share, was smaller than the USD 0.14 a share loss in those estimates. Gross Margin landed near 82% against roughly 85%, a change the company linked largely to recording branded drugs from its pharmacy at gross revenue.

Cost Cuts, Cash Position and the Fourth-Quarter Guide

LifeMD (NASDAQ:LFMD) trimmed selling and Marketing outlay by 34% versus the prior quarter, to USD 18.5 million, which pulled adjusted EBITDA to within about USD 0.41 million of breakeven. Fourth-quarter guidance points to revenue of USD 46 million to USD 49 million and an adjusted EBITDA loss of USD 4 million to USD 2 million. Cash finished the quarter at USD 21.9 million with no debt, and afterward a USD 12.5 million senior secured term Loan from Avenue Capital closed, replacing the revolving Credit facility. Active subscribers reached about 350,000, up 13% year on year, while pharmacy shipments increased 58.3%. General and administrative expense rose 6% to USD 14.7 million, and steeper marketing cuts widen margins but could slow subscriber growth.

Pharmacy Partnerships, AT&T Tie-Up and Rollout Risk

LifeMD has agreements with Novo Nordisk and Eli Lilly that let its pharmacy Supply self-pay branded GLP-1 medications nationwide, along with an exclusive arrangement with AT&T that gives that carrier's wireless and fiber subscribers and workers access to its services. The company plans to launch an enterprise healthcare product in the fourth quarter. A November 2 preview, citing published coverage, said shares had fallen roughly 29% since the prior report, so the rally follows a sharp decline. Risks include another outlook reduction, falling revenue, margin pressure and the new term loan, and LifeMD (NASDAQ:LFMD) must show that these partnerships convert into paying subscribers.

Where Things Stand

The 36.56% advance most plausibly reflects the November 12, 2026 results, though no single item has been confirmed as the cause. Despite cutting its full-year outlook and reporting lower revenue, LifeMD (NASDAQ:LFMD) posted a narrower loss, adjusted EBITDA close to breakeven, and fresh loan and GLP-1 and AT&T deals. Investors will look next at fourth-quarter revenue relative to the USD 46 million to USD 49 million range and at the enterprise product rollout.